Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution
07 Dec 2023
PDC
Preview
Source: Business Wire
Preview
Source: Business Wire
UPPSALA, Sweden--(BUSINESS WIRE)--Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, and Biotage, a global life sciences company, providing high-quality purification and sample preparation solutions, today announced a partnership to offer Biotage® PeptiPEC, based on Gyros’ PurePep® EasyClean (PEC™) catch and release technology, on Biotage® Extrahera™ automated sample preparation system. The development of an automated plate-based peptide purification workflow provides a fast and environmentally sustainable solution for high-throughput peptide purification.
Biotage PeptiPEC high-throughput kits leverage Gyros Protein Technologies’ proprietary PEC catch and release technology for automation in a plate-based format, enabling scientists to now use the technology to advance drug discovery processes. The PEC technology combined with Biotage Extrahera can purify up to 96 peptides in parallel 75% faster and 98% lower solvent consumption in comparison to sequential HPLC.
Parallel peptide synthesis generates crude peptide samples at a rate that surpasses the capacity of HPLC, the most common method of peptide purification, which is particularly evident when purifying more than 24 peptides simultaneously. The workflow enables scientists to conduct screening and development processes using purified peptides, supporting more robust and accurate processes and results.
Tomas Blomquist, CEO, Biotage, said: “We’re excited to be partnering with Gyros Protein Technologies to bring a plate-based automated solution for parallel high-throughput peptide purification to market, removing bottlenecks for peptide scientists, and providing a complete workflow solution from synthesis to evaporation. This partnership strengthens our position in the rapidly growing peptide market and supports our mission to provide high-quality, end-to-end separation and sample preparation solutions to scientists all over the world.”
Mark Vossenaar, Vice President, General Manager, Biopharmaceutical Development Division at Mesa Labs, commented: “By partnering with Biotage, we are taking a step further in our commitment to provide scientists with state-of-the-art peptide solutions across the entire value chain, from early research and screening to large-scale peptide production. The availability of our proprietary PEC purification for automation in a plate-based format is equipping researchers with faster and more sustainable processes to advance their drug discovery."
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.